Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lipid emulsion + heparin
- Development stage
- Unknown
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
Lipid emulsion + heparin is an experimental combination used in clinical and preclinical research to acutely elevate plasma free fatty acids (FFAs) or non-esterified fatty acids (NEFAs). The infusion of a lipid emulsion (such as Intralipid) alongside heparin stimulates lipoprotein lipase, which hydrolyzes the infused triglycerides into free fatty acids. This rapid elevation of circulating FFAs is widely utilized as an in vivo model to induce acute insulin resistance, allowing researchers to study the pathophysiological mechanisms of metabolic syndrome, type 2 diabetes, and lipid-induced cardiovascular or endocrine dysfunction.
- Other names
- Intralipid + heparinIntralipid/heparinlipid emulsion and heparinlipid-heparin infusionlipid/heparin infusion
02
Targets
LPL (Lipoprotein lipase)
Beyond the preview
Go deeper on lipid emulsion + heparin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lipid emulsion + heparin.